You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Submits Comments Re: Data Metrics and Alternative Processes for Access to Care in the Medicaid Program RFI

<div>
Andrew Slavitt</div>
<div>
Acting Administrator</div>
<div>
Centers for Medicare &amp; Medicaid Services</div>
<div>
Department of Health and Human Services</div>
<div>
Hubert H. Humphrey Building, Room 445-G</div>
<div>
200 Independence Avenue, SW</div>
<div>
Washington, DC 20201</div>
<div>
&nbsp;</div>
<div>
RE: Data Metrics and Alternative Processes for Access to Care in the Medicaid Program Request for Information [CMS-2328-NC]</div>
<div>
&nbsp;</div>
<div>
Dear Acting Administrator Slavitt:</div>
<div>
The Biotechnology Industry Organization (BIO) is pleased to submit comments on the Centers for Medicare and Medicaid Services&rsquo; (CMS&rsquo;s) Request for Information entitled Medicaid Program; Request for Information (RFI) &ndash; Data Metrics and Alternative Processes for Access to Care in the Medicaid Program (the &quot;RFI&quot;).&nbsp;</div>

Andrew Slavitt
Acting Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Hubert H. Humphrey Building, Room 445-G
200 Independence Avenue, SW
Washington, DC 20201
 
RE: Data Metrics and Alternative Processes for Access to Care in the Medicaid Program Request for Information [CMS-2328-NC]
 
Dear Acting Administrator Slavitt:
The Biotechnology Industry Organization (BIO) is pleased to submit comments on the Centers for Medicare and Medicaid Services’ (CMS’s) Request for Information entitled Medicaid Program; Request for Information (RFI) – Data Metrics and Alternative Processes for Access to Care in the Medicaid Program (the "RFI"). 
 
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.

See the full comment letter here.